Evidence map›Paper›PMID 36913909›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2023

The Morphologic Spectrum of Gastric Type 1 Enterochromaffin-Like Cell Neuroendocrine Tumors.

Julio C Poveda, Satyapal Chahar, Monica T Garcia-Buitrago, Elizabeth A Montgomery, Oliver G McDonald

Open access · bronzeAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Autoimmune gastritis: emerging insights and clinical management.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Julio C PovedaDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida.
Satyapal ChaharDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida.
Monica T Garcia-BuitragoDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida.
Elizabeth A MontgomeryDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida.
Oliver G McDonaldDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: ogm443@miami.edu.
University of Miami · US

Funding

SOX4-Mediated Transcription Program in Esophageal AdenocarcinomaP01CA268991 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WAEL EL-RIFAI · 2022 to 2026
$9.2M
THE EVOLUTION OF PGD ADDICTION IN HUMAN PANCREATIC CANCERR01CA222594 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Oliver Gene McDonald · 2019 to 2026
$2.5M
BLRD VA IK6 BX003787NCI NIH HHS P01 CA268991NCI NIH HHS R01 CA222594
6 · The paper itself

Abstract

Although most well-differentiated gastric neuroendocrine tumors (gNETs) arise from enterochromaffin-like (ECL) cells in patients with autoimmune metaplastic atrophic gastritis (AMAG), the morphologic spectrum of these type 1 ECL-cell gNETs is not well defined. The extent of metaplastic progression in the background mucosa of AMAG patients with gNETs is likewise unclear. Here we report the histomorphology of 226 gNETs, including 214 type 1 gNETs (78 cases from 50 AMAG patients) pooled from a population with high AMAG prevalence. Most type 1 gNETs were ≤1.0 cm, of low grade, and multifocal, consistent with the results of previous reports. However, a high proportion (70/214, 33%) displayed unusual gNET morphologies not previously appreciated in AMAG patients. Unlike other type 1 gNETs with conventional neuroendocrine tumor morphologies, unconventional type 1 gNETs displayed cribriform networks of atrophic cells embedded within myxoid matrix (secretory-cribriform variant, 59%), sheets of deceptively bland discohesive cells resembling inflammatory infiltrates (lymphoplasmacytoid variant, 31%), or wreath-like arrangements of columnar cells wrapped around collagenous cores (pseudopapillary variant, 14%). Another unusual feature was that unconventional gNETs grew laterally within the mucosa (50/70, 71%) and were only rarely sampled from the submucosa (3/70, 4%). These features also differed from the conspicuous radial nodules (99/135, 73%) and frequent submucosal involvement (57/135, 42%) observed for conventional gNETs (P < .0001). Irrespective of morphology, type 1 gNETs were nearly always detected at first AMAG diagnosis (45/50, 90%) and tended to persist thereafter (34/43, 79%), despite similar clinical symptoms and laboratory values between AMAG patients with gNETs and those without. However, unlike AMAG patients without gNETs (n = 50), the background mucosa in patients with gNETs (n = 50) had already progressed to the morphologic equivalent of end-stage metaplasia (P < .0001). This included diffuse loss of parietal cells (92% vs 52%), complete intestinal metaplasia (82% vs 40%), and pancreatic metaplasia (56% vs 6%). Thus, type 1 ECL-cell gNETs are morphologically heterogeneous with a high prevalence of unconventional gNET morphologies. They tend to present silently at first AMAG diagnosis as multifocal lesions that persist within fields of mature metaplasia.

Indexed as

Autoimmune DiseasesGastritis, AtrophicNeuroendocrine TumorsPrecancerous ConditionsStomach NeoplasmsEnterochromaffin-like CellsGastric MucosaHumansMetaplasiaAMAGautoimmuneECL cellgastricgastritismetaplasiaNETneuroendocrine

Identifiers

PMID36913909
PMCPMC10121960
OpenAlexW4313898279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.